Physician profile
Debra Browne
NPI 1316930225
$645.01
in general payments reported to CMS, 2019-2025
11 companies · $295 in 2025
The $295 reported for 2025 was more than what 84% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.41 · 2023: $243 · 2024: $40.03 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuraxis, INC. | $170.77 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $129.06 | 2025 | Dupixent |
| Abbvie INC. | $72.89 | 2021-2025 | |
| Novo Nordisk INC | $64.19 | 2025 | Sogroya |
| Laborie Medical Technologies Corp. | $53.60 | 2024-2025 | Kiwi Procup, Alphaone |
| Neurocrine Biosciences, INC. | $32.81 | 2025 | |
| Genzyme Corporation | $32.35 | 2023 | |
| Azurity Pharmaceuticals, INC. | $28.92 | 2025 | Triptodur |
| Mirum Pharmaceuticals, INC. | $24.06 | 2023 | Livmarli |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.61 | 2021 | |
| Ucb, INC. | $15.75 | 2023 | Fintepla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Browne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.